Viruses (Oct 2022)
Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection
- Alexander J. McAuley,
- Petrus Jansen van Vuren,
- Muzaffar-Ur-Rehman Mohammed,
- Faheem,
- Sarah Goldie,
- Shane Riddell,
- Nathan J. Gödde,
- Ian K. Styles,
- Matthew P. Bruce,
- Simran Chahal,
- Stephanie Keating,
- Kim R. Blasdell,
- Mary Tachedjian,
- Carmel M. O’Brien,
- Nagendrakumar Balasubramanian Singanallur,
- John Noel Viana,
- Aditya V. Vashi,
- Carl M. Kirkpatrick,
- Christopher A. MacRaild,
- Rohan M. Shah,
- Elizabeth Vincan,
- Eugene Athan,
- Darren J. Creek,
- Natalie L. Trevaskis,
- Sankaranarayanan Murugesan,
- Anupama Kumar,
- Seshadri S. Vasan
Affiliations
- Alexander J. McAuley
- Australian Centre for Disease Preparedness, Commonwealth Scientific and Industrial Research Organisation, Portarlington Road, Geelong, VIC 3220, Australia
- Petrus Jansen van Vuren
- Australian Centre for Disease Preparedness, Commonwealth Scientific and Industrial Research Organisation, Portarlington Road, Geelong, VIC 3220, Australia
- Muzaffar-Ur-Rehman Mohammed
- Department of Pharmacy, Birla Institute of Technology and Science, Pilani 333031, India
- Faheem
- Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT 84112, USA
- Sarah Goldie
- Australian Centre for Disease Preparedness, Commonwealth Scientific and Industrial Research Organisation, Portarlington Road, Geelong, VIC 3220, Australia
- Shane Riddell
- Australian Centre for Disease Preparedness, Commonwealth Scientific and Industrial Research Organisation, Portarlington Road, Geelong, VIC 3220, Australia
- Nathan J. Gödde
- The Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4075, Australia
- Ian K. Styles
- Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
- Matthew P. Bruce
- Australian Centre for Disease Preparedness, Commonwealth Scientific and Industrial Research Organisation, Portarlington Road, Geelong, VIC 3220, Australia
- Simran Chahal
- Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC 3000, Australia
- Stephanie Keating
- Australian Centre for Disease Preparedness, Commonwealth Scientific and Industrial Research Organisation, Portarlington Road, Geelong, VIC 3220, Australia
- Kim R. Blasdell
- Australian Centre for Disease Preparedness, Commonwealth Scientific and Industrial Research Organisation, Portarlington Road, Geelong, VIC 3220, Australia
- Mary Tachedjian
- Australian Centre for Disease Preparedness, Commonwealth Scientific and Industrial Research Organisation, Portarlington Road, Geelong, VIC 3220, Australia
- Carmel M. O’Brien
- Manufacturing, Commonwealth Scientific and Industrial Research Organisation, Research Way, Clayton, VIC 3168, Australia
- Nagendrakumar Balasubramanian Singanallur
- Australian Centre for Disease Preparedness, Commonwealth Scientific and Industrial Research Organisation, Portarlington Road, Geelong, VIC 3220, Australia
- John Noel Viana
- Australian National Centre for the Public Awareness of Science, Australian National University, Canberra, ACT 2601, Australia
- Aditya V. Vashi
- Manufacturing, Commonwealth Scientific and Industrial Research Organisation, Research Way, Clayton, VIC 3168, Australia
- Carl M. Kirkpatrick
- Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
- Christopher A. MacRaild
- Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
- Rohan M. Shah
- Department of Chemistry and Biochemistry, Swinburne University of Technology, Hawthorn, VIC 3122, Australia
- Elizabeth Vincan
- Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC 3000, Australia
- Eugene Athan
- School of Medicine, Deakin University, Pigdons Road, Waurn Ponds, VIC 3216, Australia
- Darren J. Creek
- Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
- Natalie L. Trevaskis
- Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
- Sankaranarayanan Murugesan
- Department of Pharmacy, Birla Institute of Technology and Science, Pilani 333031, India
- Anupama Kumar
- Land & Water, Commonwealth Scientific and Industrial Research Organisation, Waite Campus, Urrbrae, SA 5064, Australia
- Seshadri S. Vasan
- Australian Centre for Disease Preparedness, Commonwealth Scientific and Industrial Research Organisation, Portarlington Road, Geelong, VIC 3220, Australia
- DOI
- https://doi.org/10.3390/v14112417
- Journal volume & issue
-
Vol. 14,
no. 11
p. 2417
Abstract
The repurposing of licenced drugs for use against COVID-19 is one of the most rapid ways to develop new and alternative therapeutic options to manage the ongoing pandemic. Given circa 7817 licenced compounds available from Compounds Australia that can be screened, this paper demonstrates the utility of commercially available ex vivo/3D airway and alveolar tissue models. These models are a closer representation of in vivo studies than in vitro models, but retain the benefits of rapid in vitro screening for drug efficacy. We demonstrate that several existing drugs appear to show anti-SARS-CoV-2 activity against both SARS-CoV-2 Delta and Omicron Variants of Concern in the airway model. In particular, fluvoxamine, as well as aprepitant, everolimus, and sirolimus, has virus reduction efficacy comparable to the current standard of care (remdesivir, molnupiravir, nirmatrelvir). Whilst these results are encouraging, further testing and efficacy studies are required before clinical use can be considered.
Keywords
